Skip to nav Skip to content

Hematologic cancers such as leukemia, lymphoma and myeloma develop in the bone marrow, where blood is produced. Within the bone marrow, all blood cells originate from an unspecialized stem cell. When a stem cell divides, it initially becomes an immature red blood cell, white blood cell or platelet-producing cell, which then divides and develops into a mature red blood cell, white blood cell or platelet.

Members of the Malignant Hematology Program

For reasons that aren’t yet fully understood within the general medical community, the blood cell development process sometimes goes awry, and pieces of blood cell chromosomes get rearranged. The resulting abnormal chromosomes can interfere with normal cell division, causing the affected cells to divide uncontrollably or become resistant to natural cell death. Eventually, abnormal blood cells may outnumber healthy blood cells and interfere with their function, resulting in the development of blood cancer. Most hematologic malignancies are very complex and require specialized expertise to successfully treat.

Refer your patients to our nationally lauded program

Moffitt Cancer Center welcomes referrals of patients who have a suspected hematologic condition or are seeking treatment for a confirmed diagnosis. Our nationally lauded Malignant Hematology Program specializes in the diagnosis and treatment of blood cancers and autoimmune disorders, and we are dedicated to providing exceptional care by developing a tailored treatment plan for each patient. Our multispecialty team includes nearly two dozen hematologic-oncologists, all of whom are foremost experts in their respective specialties, such as medical oncology or pathology.

Additionally, as a high-volume cancer center, Moffitt treats patients with all types of hematologic malignancies, including rare blood-based liquid tumors and autoimmune abnormalities. As such, your patients can benefit from our unparalleled expertise in the management of conditions such as lymphoma, leukemia and myelodysplastic syndromes (MDS), as well as multiple myeloma, myeloproliferative syndromes, aplastic anemia and other hematological malignancies.

An invaluable resource for you & your patients

Serving as a resource for referring physicians nationwide, Moffitt’s Malignant Hematology Program offers:

  • Complete diagnostic workups, including on-site lab work, light microscopies, cytogenetic testing/immunophenotyping and bone marrow aspirations and biopsies
  • Comprehensive screening, staging and pathology services
  • The latest chemotherapy drugs and drug combinations along with access to peripheral stem cell support
  • Innovative treatment options such as immunotherapies, infusions, liposomal drug delivery, anti-angiogenesis therapies, experimental vaccines, monoclonal antibodies, inhibitor treatments and cytokine therapies
  • Rapid access to bone marrow transplants through our joint effort with our Bone and Marrow Transplant and Cellular Immunotherapy Program
  • Pain management, dietary counseling and other supportive care services provided by our dedicated Pharmacy and Supportive Care team

Our patients also have access to promising new treatments through our robust clinical trials program. For information about the clinical trials currently underway at Moffitt, contact us at 813-745-6100 or 1-800-679-0775 (toll-free) or complete and submit aclinical trials inquiry form online.

Through our individualized and comprehensive approach to patient care, Moffitt routinely achieves outcomes that are comparable to or better than national averages—even for some hematologic malignancies that are known to be highly resistant to treatment. Furthermore, we emphasize short referral times and schedule most new patient appointments within a few days.

If you’d like to refer a patient to a hematologist-oncologist at Moffitt Cancer Center, complete our online form or contact aphysician liaison for assistance or support.